A systematic review and meta-analysis of 68 diagnostic cohort studies (14 037 patients) suggests that no one feature is more impactful that the combination of symptoms, signs, and laboratory tests to diagnose the presence giant cell arteritis (GCA).
From these analyses findings associated with a diagnosis of GCA included:
Dr. John Cush RheumNow
6 years 1 month ago
Telemedicine: What's Changed and What Needs to be Addressed? An update on legislative changes, uncertainties, and the care gap post COVID https://t.co/HRAsEP7IL6 https://t.co/X6PL0W4tI7
Dr. John Cush RheumNow
6 years 1 month ago
Gilead/Galapagos gets a setback for filgotinib, its JAK1 inhib, that was poised to be the next approved RA drug by FDA. Instead the FDA issued a complete response letter; citing concerns over sperm studies (MANTA, MANTA-RAy) & 200 mg dose. Delay till 2021? https://t.co/H0rLjOMXq8 https://t.co/vb4FDUUVoS
Dr. John Cush RheumNow
6 years 1 month ago
RheumNow Podcast - The Bad News That's Fit to Print (8.21.20)
Dr Jack Cush reviews this week highlights filgotinib rejection, delays in Diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX
https://t.co/1oZtU14VOB https://t.co/rcWlbYVKYn
Dr. John Cush RheumNow
6 years 1 month ago
The FDA approves Novartis'anti-CD20 mAb, Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis (MS). https://t.co/2DgA4Modds
Dr. John Cush RheumNow
6 years 1 month ago
RheumNow Podcast The Bad News That's Fit to Print - highlights filgotinib rejection, Dx delays, metformin in COVID, Abx & IBD, UPA beats MTX. Watch here> https://t.co/PV6b2wcanD or listen to the podcast on iTunes> https://t.co/FHJv01AAbC or SoundCloud> https://t.co/1oZtU14VOB
Dr. John Cush RheumNow
6 years 1 month ago
ATS Abstract: n=616 survey contrasts rheums (57%) & pulmonologists (43%) beliefs on RA associated ILD. Both preferred to use steroids, MMF, RTX for RA-ILD, but Rheums tend avoid ADA & LEF. Rheums (17%) & Pulms (24%) think MTX a risk factor https://t.co/W5gbu84FBv
Dr. John Cush RheumNow
6 years 1 month ago
Metanalysis of total elbow arthroplasty in RA - 38 studies, 2,118 TEAs w/ mean F/U of 819 mos - the implant failure & complication rates were 16% & 24%. Aseptic loosening was most common failure (9.5%). Higher failures in younger pts & unlinked design https://t.co/Pq2N1Kku60
The Journal of Rheuatology reports a pooled analysis of patients from 16 observational RA registries that examined the association between seropositivity (RF or ACPA) with biologic DMARDs responses; they showed better clinical responses when seropositive RA patients receive abatacept (ABA) or rituximab (RTX).
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow: filgotinib rejection, delays in diagnosis, metformin benefits COVID, Abx and IBD, and UPA beats MTX.
U.S. FDA US_FDA
6 years 1 month ago
To date, the FDA has currently authorized 218 tests under EUAs; these include 176 molecular tests, 39 antibody tests, and 3 antigen tests.
Peter Nash drpnash
6 years 1 month ago
@RheumNow its time we stopped “seroneg RA” which are many diseases, like ANCA pos Vasculitis we should have ACPA pos RA and others - how many viral arthritides in our country “doing great” on SZP, PLAQ, or low dose MTX and reluctant to stop? #RA #Seronegative
Dr. John Cush RheumNow
6 years 1 month ago
Mayo clinic: Theres a delay in diagnosing Seronegative RA - 1st joint swelling to diagnosis of RA was 187 days for seroneg vs 11 days for seropositive patients (P<.001). Seronegative RA less likely to achieve remission (28% vs 50% at 5 years) (P=.007) https://t.co/Hgewjmt1CL
Dr. John Cush RheumNow
6 years 1 month ago
Study of 2 Canadian centers finds amongst 2095 patients taking biologics for #Psoriasis, 23 (1.1%) stopped their biologic for "COVID-19 related concerns". 5/23 restarted biologic for PSO flares. This included TNFi, inhibitors of IL17, IL12/23, IL23 https://t.co/gjSX4P0LMK
